MedTrace Logo

Combination Therapy in Amyotrophic Lateral Sclerosis (ALS)

NCT00919555 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2012-11-30

No results posted yet for this study

Summary

The purpose of the study is to determine the safety and the efficacy of Tretinoin and Pioglitazone HCL in patients with ALS who are currently on Riluzole.

Conditions

Interventions

DRUG

Pioglitazone and Tretinoin

Tretinoin: 1 pill twice a day (10 mg/bid) Pioglitazone HCL: 1 pill once a day (30 mg/qd)

DRUG

Tretinoin and Pioglitazone HCL

Tretinoin 10 mg 1 pill po twice a day Pioglitazone HCL 30 mg 1 pill po once a day

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Phoenix Neurological Associates, LTD

    lead OTHER

Principal Investigators

  • Todd D Levine, MD · Phoenix Neurological Associates, LTD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-11-30
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00919555 on ClinicalTrials.gov